Cargando…

Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data

In this study, we investigate SimulAD, a novel quantitative instrument for the development of intervention strategies for disease-modifying drugs in Alzheimer's disease. SimulAD is based on the modeling of the spatio-temporal dynamics governing the joint evolution of imaging and clinical biomar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abi Nader, Clément, Ayache, Nicholas, Frisoni, Giovanni B, Robert, Philippe, Lorenzi, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168944/ https://www.ncbi.nlm.nih.gov/pubmed/34085040 http://dx.doi.org/10.1093/braincomms/fcab091

Ejemplares similares

Longitudinal Analysis of Image Time Series with Diffeomorphic Deformations: A Computational Framework Based on Stationary Velocity Fields
por: Hadj-Hamou, Mehdi, et al.
Publicado: (2016)

Simulating Longitudinal Brain MRIs with Known Volume Changes and Realistic Variations in Image Intensity
por: Khanal, Bishesh, et al.
Publicado: (2017)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
por: Daniela, Perani, et al.
Publicado: (2014)

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
por: Collij, Lyduine E., et al.
Publicado: (2023)

Erratum to “A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis”
por: Perani, Daniela, et al.
Publicado: (2014)

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
por: Cotta Ramusino, Matteo, et al.
Publicado: (2021)

Technical aspects of amyloid imaging for Alzheimer's disease
por: Edison, Paul, et al.
Publicado: (2011)

Comparison of the amyloid pore forming properties of rat and human Alzheimer’s beta-amyloid peptide 1-42: Calcium imaging data
por: Di Scala, Coralie, et al.
Publicado: (2016)

Amyloid PET imaging: applications beyond Alzheimer’s disease
por: Catafau, Ana M., et al.
Publicado: (2015)

Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease
por: Luo, Ziyi, et al.
Publicado: (2021)

Using amyloid PET imaging to diagnose Alzheimer’s disease in patients with multiple sclerosis
por: Kolanko, Magdalena, et al.
Publicado: (2020)

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
por: Withington, Charles G., et al.
Publicado: (2022)

The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging
por: Bommarito, Giulia, et al.
Publicado: (2022)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science
por: Gietl, Anton F., et al.
Publicado: (2022)

Identifying highly heritable brain amyloid phenotypes through mining Alzheimer’s imaging and sequencing biobank data
por: Bao, Jingxuan, et al.
Publicado: (2022)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Electroencephalographic Rhythms in Alzheimer's Disease
por: Lizio, Roberta, et al.
Publicado: (2011)

Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer’s disease: how and what to tell. A kickstart to an ethical discussion
por: Porteri, Corinna, et al.
Publicado: (2014)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Amyloid imaging in clinical trials
por: Ossenkoppele, Rik, et al.
Publicado: (2013)

Multiplex connectome changes across the alzheimer’s disease spectrum using gray matter and amyloid data
por: Canal-Garcia, Anna, et al.
Publicado: (2022)

Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer’s disease
por: Winkeler, A., et al.
Publicado: (2008)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

In vivo Image of Cerebral Amyloid Angiopathy in an Alzheimer's Disease Mouse Model
por: Kim, Jinho, et al.
Publicado: (2015)

Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease
por: Tong, Hongjuan, et al.
Publicado: (2015)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Structural Variation in Amyloid-β Fibrils from Alzheimer’s Disease Clinical Subtypes
por: Qiang, Wei, et al.
Publicado: (2017)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
por: Fedele, Ernesto
Publicado: (2023)

Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?
por: Merlo Pich, Emilio, et al.
Publicado: (2014)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease()
por: Chételat, Gaël, et al.
Publicado: (2013)

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease
por: Sehlin, Dag, et al.
Publicado: (2016)

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
por: Maschio, Cinzia, et al.
Publicado: (2022)

Amyloid imaging for dementia in clinical practice
por: O’Brien, John T., et al.
Publicado: (2015)

Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology
por: Martersteck, Adam, et al.
Publicado: (2022)

Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease
por: Moretti, Davide V., et al.
Publicado: (2011)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_t28r8d711o0qqsm8prem0oqf3a